华特达因(000915) - 2022 Q3 - 季度财报

Financial Performance - For the first nine months of 2022, the company achieved a revenue of CNY 1.819 billion, representing a year-on-year growth of 15.67%[5] - The net profit attributable to shareholders for the same period was CNY 462 million, an increase of 45.10% compared to the previous year[5] - The subsidiary, Shandong Dain Marine Biological Pharmaceutical Co., Ltd., reported a revenue of CNY 526 million in Q3 2022, up 33.58% year-on-year, and a net profit of CNY 283 million, which is a 68.83% increase[5] - The net profit for the first nine months was CNY 865 million, a 46.22% increase driven by growth in the pharmaceutical business[15] - The net profit for the third quarter was 865,038,482.33 CNY, an increase of 46.1% compared to 591,605,152.82 CNY in the same period last year[30] - The total comprehensive income attributable to the parent company's owners was 462,412,455.71 CNY, compared to 318,686,318.58 CNY in the previous year, reflecting a growth of 45%[30] - The company reported a total profit of 1,009,123,751.74 CNY, up from 693,224,944.16 CNY year-over-year, representing a 45.5% increase[30] Assets and Liabilities - The total assets of the company at the end of the reporting period reached CNY 4.595 billion, a growth of 16.76% from the end of the previous year[7] - Total liabilities rose to CNY 666,435,393.06, compared to CNY 536,028,235.88, marking an increase of 24.3%[26] - The equity attributable to shareholders increased to CNY 2.520 billion, reflecting a year-on-year growth of 12.25%[7] - The equity attributable to shareholders increased to CNY 2,519,636,676.14 from CNY 2,244,689,408.43, a growth of 12.2%[26] - The company's retained earnings reached CNY 2,094,102,952.03, up from CNY 1,819,155,684.32, reflecting an increase of 15.1%[26] Cash Flow and Investments - The net cash flow from operating activities for the first nine months was CNY 945 million, showing a growth of 55.40% year-on-year[7] - Cash flow from operating activities generated a net amount of 945,513,109.09 CNY, compared to 608,444,452.56 CNY in the same period last year, indicating a 55.4% increase[33] - Investment activities resulted in a net cash outflow of 98,191,382.59 CNY, an improvement from a net outflow of 962,673,685.57 CNY in the same period last year[36] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,742[16] - Shandong Huate Holding Group Co., Ltd. holds 22.00% of shares, totaling 51,544,340 shares[16] - Hong Kong Central Clearing Limited holds 3.03% of shares, totaling 7,106,965 shares[16] - The company has a total of 10 major shareholders, with the top 10 holding significant stakes[16] - The company has not reported any pledged or frozen shares among the top shareholders[16] - The report indicates no known relationships or concerted actions among the major shareholders[19] Operational Highlights - Total operating revenue for the third quarter was CNY 1,818,732,732.71, an increase of 15.7% compared to CNY 1,572,409,826.06 in the same period last year[26] - Total operating costs decreased to CNY 831,485,865.51 from CNY 906,185,041.84, representing a reduction of approximately 8.2%[26] - The company reported a significant increase in accounts receivable by 70.73% to CNY 101 million, attributed to the growth in sales revenue[12] - The company’s contract liabilities rose by 73.88% to CNY 190 million, indicating an increase in advance payments received[15] - The company reported a significant increase in accounts payable, which rose to CNY 32,729,985.06 from CNY 70,563,649.54, indicating a decrease of 53.7%[23] Future Plans - The company has plans for market expansion and new product development, although specific figures were not disclosed in the report[28] Earnings Per Share - The basic earnings per share for Q3 2022 was CNY 0.67, marking a 76.36% increase compared to the same period last year[7] - Basic and diluted earnings per share were both 1.97 CNY, up from 1.36 CNY year-over-year[32]